Patents Examined by Frederick E. Waddell
  • Patent number: 5446041
    Abstract: Disclosed is an intraocular pressure reducing method and composition wherein 11-acyl prostaglandins are contained in a pharmaceutically acceptable excipient for topical application to the surface of the eye.
    Type: Grant
    Filed: October 10, 1990
    Date of Patent: August 29, 1995
    Assignee: Allergan, Inc.
    Inventors: Ming F. Chan, David F. Woodward
  • Patent number: 5420162
    Abstract: The present invention relates to a method of inhibiting the protein kinase C-mediated biological response inflammation. The method comprises administering to a mammal a non-tumor promoting 12-deoxyphorbol ester. Phorbol esters suitable for use in the method include 12-deoxyphorbol 13-monoesters wherein the ester is a formate, acetate, propionate, butyrate, pentanoate, hexanote, benzoate or phenylacetate ester. The invention also relates to novel 12-deoxyphorbol 13-monoesters, wherein the ester can be a formate, propionate, butyrate or pentanoate ester, and to pharmaceutical compositions comprising same.
    Type: Grant
    Filed: July 31, 1992
    Date of Patent: May 30, 1995
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Peter M. Blumberg, Zoltan Szallasi
  • Patent number: 5369111
    Abstract: Sensitizing tumoral cells to anticancerous drugs and/or inhibiting the tumoral cells resistance to antitumoral drugs employing as a modulator agent a vinca alkaloid dimer, analog to vinblastine or vincristine, with a low cytotoxicity or devoid of cytotoxicity, comprising at least one stereoisomerism different from that of vinblastine or vincristine in the C-14', C-16' or C-20' position. Notably, the modulator agent may have the R absolute configuration in the C-16' position.
    Type: Grant
    Filed: June 19, 1992
    Date of Patent: November 29, 1994
    Assignee: University of Vermont
    Inventors: Martin E. Kuehne, Linda S. Borman
  • Patent number: 5338761
    Abstract: An emulsified composition having an average particle size of 0.010 to 0.070 .mu.m contains at least the following components (A), (B) and (C):(A) a lipid-soluble drug and a lipid;(B) glycerol and water;(C) a phospholipid and/or a water-soluble nonionic surfactant having a molecular weight of 1000 or more, with (A)/(C) being 0.5 to 5 (weight ratio).
    Type: Grant
    Filed: September 28, 1989
    Date of Patent: August 16, 1994
    Assignee: Shiseido Company Ltd.
    Inventors: Hideo Nakajima, Miyuki Kohchi, Satoshi Tomomasa
  • Patent number: 5336691
    Abstract: This invention relates to a composition comprising a tramadol material and acetaminophen, and its use. As used herein tramadol refers to various forms of tramadol. The compositions are pharmacologically useful in treating pain and tussive conditions. The compositions are also subject to less opioid side-effects such as abuse liability, tolerance, constipation and respiratory depression. Furthermore, where the components of the compositions are within certain ratios the pharmacological effects of the compositions are superadditive (synergistic).
    Type: Grant
    Filed: November 10, 1992
    Date of Patent: August 9, 1994
    Assignee: McNeilab, Inc.
    Inventors: Robert B. Raffa, Jeffrey L. Vaught
  • Patent number: 5334593
    Abstract: The present invention relates to an anxiolytic drug comprising as an active ingredient a 1-amino-5-halogenouracil represented by formula [I]: ##STR1## wherein X represents a halogen atom, or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 9, 1992
    Date of Patent: August 2, 1994
    Assignee: Yamasa Shoyu Kabushiki Kaisha
    Inventors: Masahiro Imaizumi, Shinji Sakata
  • Patent number: 5334617
    Abstract: The present invention relates to compositions and methods for inhibiting protein aging. Accordingly, a composition is disclosed which comprises an agent or compound capable of inhibiting the formation of advanced glycosylation end products of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents are amino acids and their derivatives which contain an active nitrogen-containing group. Particular agents comprise lysine and mixtures thereof. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.
    Type: Grant
    Filed: January 27, 1992
    Date of Patent: August 2, 1994
    Assignees: The Rockefeller University, Alteon Inc.
    Inventors: Peter C. Ulrich, Anthony Cerami
  • Patent number: 5334615
    Abstract: A composition embraces an oil, for instance, a mineral oil, animal oil, or plant or vegetable oil, in combination with an acetal that can release aldehyde functionality on aqueous contact. It may be used in a method for kill or control of bacterium or virus for a suitable part of a human being or animal subject. For example, a 5% mineral oil and 2,2'-trimethylenebis(1,3-dioxolane) mixture can be used as a microbiocidal lubricant for drill bits in dentistry, or a suitably formulated composition may be used topically.
    Type: Grant
    Filed: December 17, 1992
    Date of Patent: August 2, 1994
    Inventor: Wilhelm E. Walles
  • Patent number: 5332579
    Abstract: A nutritional supplement, functioning as a food for special dietary use, enhances diets and assists persons recovering from addiction to health damaging substances. Since cellular damage and deficiencies occur and continue to exist even after the person has stopped abusing the substances, use of the nutritional supplement, which contains a variety of minerals, vitamins, herbs, amino acids, and other substances and nutrients, should be continuous. The nutritional supplement consists of a mixture of nutrients which cooperate synergistically in enhancing cellular metabolic pathways and assists in normalization of cellular functions and optimization of cellular health.
    Type: Grant
    Filed: November 20, 1992
    Date of Patent: July 26, 1994
    Inventor: Anthony J. Umbdenstock
  • Patent number: 5332838
    Abstract: The present invention is a cyclization process utilizing the catalyst copper aluminum borate which process comprises the step of contacting (1) a compound having a fragment in which a carbon-containing chain of at least three atoms in sequence is bonded at one end thereof to a nitrogen, oxygen, or sulfur atom, and at the opposite end to a carbon, nitrogen, oxygen, or sulfur atom, where the latter are bonded to at least one hydrogen atom; with (2) a catalyst comprising at least one member selected from the group consisting of copper aluminum borate and zero valent copper on a support comprising aluminum borate, under conditions sufficient to effect ring closure between the ends of the fragment to obtain a compound comprising a heterocyclic ring.
    Type: Grant
    Filed: March 29, 1988
    Date of Patent: July 26, 1994
    Assignee: Amoco Corporation
    Inventors: Patrick E. McMahon, Larry C. Satek
  • Patent number: 5332747
    Abstract: The specification discloses a method for enhancing the inhibiting action of drugs against multidrug resistant cells, representing various parasitic diseases, apparently by reversing the glycoprotein "pumps" associated with such cells.
    Type: Grant
    Filed: June 13, 1990
    Date of Patent: July 26, 1994
    Assignee: Cancer Biologics of America, Inc.
    Inventor: Knox Van Dyke
  • Patent number: 5332567
    Abstract: A method of targeting a diagnostic or therapeutic agent to a focus of infection comprises injecting a patient infected with a pathogen parenterally with an antibody conjugate which specifically binds to an accessible epitope of the pathogen or of a pathogen-associated antigen accreted at the focus of infection, the antibody conjugate further comprising a bound diagnostic or therapeutic agent for detecting, imaging or treating the infection. Polyspecific composite conjugates enhance the efficacy of the method, which is especially useful for treating infections that are refractory towards systemic chemotherapy.
    Type: Grant
    Filed: March 22, 1993
    Date of Patent: July 26, 1994
    Assignee: Immunomedics
    Inventor: M. David Goldenberg
  • Patent number: 5331012
    Abstract: The present invention relates to a method and pharmaceutical composition for treating fever blisters or cold sores in mammals, and particularly in humans, by topically administering a pharmaceutical composition comprising ethyl alcohol in a concentration of at least 85% W/V and lidocaine in a concentration of 0.5-10% W/V at a periodicity of at least 10 to 12 times daily.
    Type: Grant
    Filed: March 5, 1992
    Date of Patent: July 19, 1994
    Inventors: Kenneth B. Riddick, Joe G. Matheson, Jr., Louis E. Mizelle, Jr.
  • Patent number: 5330993
    Abstract: This invention relates to a novel class of immunosuppressive compounds having an affinity for the FK-506 binding protein (FKBP). Once bound to this protein, the immunosuppressive compounds inhibit the prolyl peptidyl cis-trans isomerase (rotamass) activity of the FKBP and inhibit T cell activation. As such, the compounds of this invention can be used as immunosuppressive drugs to prevent or significantly reduce graft rejection in bone marrow and organ transplantations and for use in the treatment of a wide variety of autoimmune diseases in humans and other mammals.
    Type: Grant
    Filed: July 2, 1991
    Date of Patent: July 19, 1994
    Assignee: Vertex Pharmaceuticals, Inc.
    Inventors: David M. Armistead, Joshua S. Boger, Harold V. Meyers, Jeffrey O. Saunders, Roger D. Tung
  • Patent number: 5330744
    Abstract: The present invention provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises treating the cells so as to render them resistant to an antitumor agent and contacting the resulting resistant cells under suitable conditions with an amount of a compound effective to selectively induce terminal differentiation of such cells. The compound has a structure:[R-A ]-B-[A.sub.1 -B.sub.1 -].sub.a [A.sub.2 -B.sub.2 -].sub.b [A.sub.3 -R.sub.1 ].The invention also concerns a method of treating a patient having a tumor characterized by proliferation of neoplastic which comprises administering to the patient an amount of an antitumor agent to render the cells resistant to the antitumor agent and subsequently administering to the patient an amount of the compound effective to selectively induce terminal differentiation of such neoplastic cells and thereby inhibit their proliferation.
    Type: Grant
    Filed: November 14, 1988
    Date of Patent: July 19, 1994
    Assignees: Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York
    Inventors: Sandro Pontremoli, Ronald Breslow, Paul A. Marks, Richard A. Rifkind
  • Patent number: 5328913
    Abstract: The present invention relates to a method of inhibiting cell proliferation and lysyl hydroxylase expression. The method involves the use of minoxidil derivatives. The inhibitory activity of hydroxy derivatives of minoxidil is such that these compounds can be used as selective antifibrotic agents.
    Type: Grant
    Filed: December 11, 1992
    Date of Patent: July 12, 1994
    Assignee: Duke University
    Inventors: Saood Murad, Sheldon R. Pinnell
  • Patent number: 5326779
    Abstract: The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, composition is disclosed which comprises 1,2-disubstituted benzimidazoles capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.
    Type: Grant
    Filed: December 8, 1992
    Date of Patent: July 5, 1994
    Assignees: The Rockefeller University, Alteon Inc.
    Inventors: Peter C. Ulrich, Anthony Cerami, Dilip R. Wagle
  • Patent number: 5324513
    Abstract: The invention concerns a composition useful for the manufacture of vaccines containing particles having the immunogenic properties characteristic of the antigen HBsAg, these particles being more particularly characterized by the fact that the said particles equally contain a receptor for polymerized human albumin. They are obtained by transformation of human or animal cells by a vector containing a DNA sequence coding for the S and pre-S regions of a genome of viral hepatitis B, this DNA sequence being placed under the direct control of a promoter permitting the effective transcription of the said sequence in the human or animal cells transformable by the said vector.
    Type: Grant
    Filed: February 28, 1991
    Date of Patent: June 28, 1994
    Assignees: Institut Pasteur, Institut National De La Sante Et De La Rocherche Medicale, Centre National De La Recherche Scientifique
    Inventors: Eliane Sobczak, Yves Malpiece, deceased, Marie-Louise Michel, Pierre Tiollais, Rolf E. Streeck
  • Patent number: 5324745
    Abstract: A pesticidal organotin formulation is a water dispersible solid concentrate comprising at least one pesticidal organotin compound and polyvinylpyrrolidone. The formulation is prepared by dissolving the organotin compound and the polyvinylpyrrolidione in a solvent, followed by removal of the solvent, preferably by evaporation at a pressure below atmospheric pressure to yield the solid concentrate. The formulation may be dispersed in water, either with or without agitation, to yield an aqueous dispersion which may be applied to a locus to combat pests, especially acarids.
    Type: Grant
    Filed: August 6, 1990
    Date of Patent: June 28, 1994
    Assignee: Shell Research Limited
    Inventors: Michael G. Sayer, Alister C. Hill, Teresa J. Reid, Brian D. Steer
  • Patent number: 5324840
    Abstract: Compounds that provide non-teratogenic effects and lack irritation to the skin are shown in the formula below where the partially drawn ring signifies an aromatic ring which may be carbocyclic or heteroaromatic, 6-membered or 5-membered, and may be condensed with another ring. R.sub.1 is lower alkyl, Cl, Br, or I, R.sub.2 is H, lower alkyl, Cl, Br, or I, and R.sub.3 is lower alkyl, Cl, Br, I, or is an ether, thioether, ester, thioester, amine or substituted amine group.
    Type: Grant
    Filed: June 11, 1992
    Date of Patent: June 28, 1994
    Assignee: Allergan, Inc.
    Inventor: Roshantha A. S. Chandraratna